The PD-1 expressing immune phenotype of T cell exhaustion is prominent in the ‘immunoreactive’ microenvironment of colorectal carcinoma

Histopathology

Volumn 71, Issue 3, 2017, Pages 366-374

  Prall, Friedrich ^a   Hühns, Maja ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

anti tumour immunity; colorectal cancer; PD 1; T cell exhaustion; tumour infiltrating lymphocytes

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHLORDANE; GRANZYME B; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN S 100; TRANSCRIPTION FACTOR FOXP3; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER;

ARTICLE; CELL COUNTING; CELL DENSITY; CLUSTER ANALYSIS; COLORECTAL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TISSUE MICROARRAY; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; BIOSYNTHESIS; COLORECTAL TUMOR; IMMUNOLOGY; PATHOLOGY; PHENOTYPE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; PHENOTYPE; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85020475365     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.13231     Document Type: Article

References (30)

1. Naito Y, Saito K, Shiiba K et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998; 58; 3491–3494.
2. Guidoboni M, Gafa R, Viel A et al. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am. J. Pathol. 2001; 159; 297–304.
3. Linnebacher M, Gebert J, Rudy W et al. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int. J. Cancer 2001; 93; 6–11.
4. Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int. Immunol. 2014; 27; 33–46.
5. Wherry JE. T cell exhaustion. Nat. Immunol. 2011; 12; 492–499.
6. Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann. Oncol. 2016; 27; 409–416.
7. Ostrand-Rosenberg S, Horn LA, Haile ST. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J. Immunol. 2014; 193; 3835–3841.
8. Kim JH, Park HE, Cho N-Y, Lee HS, Kang HG. Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers. Br. J. Cancer 2016; 115; 490–496.
9. Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod. Pathol. 2016; 29; 1104–1112.
10. Prall F, Hühns M. PD-L1 expression in tumour buds of colorectal carcinoma. Histopathology 2016; 69; 158–159.
11. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 2015; 372; 2509–2520.
12. Dierssen JWF, de Miranda NFCC, Ferrone S et al. HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. BMC Cancer 2007; 7; 33–44.
13. Ling A, Edin S, Wikberg ML, Öberg Å, Palmqvist R. The intratumoural subsite and relation of CD8+ and FOXP3+ T lymphocytes in colorectal cancer provide important prognostic clues. Br. J. Cancer 2014; 110; 2551–2559.
14. De Smedt L, Lemahieu J, Palmans S et al. Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis. Br. J. Cancer 2015; 113; 500–509.
15. Ogino S, Cantor M, Kawasaki T et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006; 55; 1000–1006.
16. Ostwald C, Linnebacher M, Weirich V, Prall F. Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification. Int. J. Oncol. 2009; 35; 321–327.
17. Van den Brand M, Hoevenaars BM, Sigmans JHM et al. Sequential immunohistochemistry: a promising new tool for the pathology laboratory. Histopathology 2014; 65; 651–657.
18. Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell 2009; 138; 30–50.
19. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439; 682–687.
20. Liu J, Zhang S, Hu Y et al. Targeting PD-1 and TIM-3 pathways to reverse CD8 T cell exhaustion and enhance ex-vivo T cell responses to autologous dendritic/tumor vaccines. J. Immunother. 2016; 39; 171–180.
21. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986; 315; 1650–1659.
22. Jass JR, Atkin WS, Cuzick J et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology 1986; 10; 437–459.
23. Harrison JC, Dean PJ, El-Zeky F, Vander Zwaag R. From Dukes through Jass: pathological indicators in rectal cancer. Hum. Pathol. 1994; 25; 498–505.
24. Prall F, Dührkop T, Weirich V et al. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum. Pathol. 2004; 35; 808–816.
25. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313; 1960–1964.
26. Xiao Y, Freeman GJ. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov. 2015; 5; 16–18.
27. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487; 330–337.
28. Gong J, Wang C, Lee PP, Chu P, Fakih M. Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutation. J. Natl. Compr. Canc. Netw. 2017; 15; 142–147.
29. Allard MA, Bachet JB, Beauchet A et al. Linear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor. Diagn. Pathol. 2012; 7; 156–167.
30. Galon J, Mlecnik B, Bindea G et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J. Pathol. 2014; 232; 199–209.